RxDoctor Payments DataLook up a doctor →

Nancy Berube, MD

Family Medicine · Worcester, MANPI 1538131867

Payments from drug & device makers

$14,130in general payments, 2019–2025

Across 708 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$2K
  • Pfizer$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Teva Pharmaceuticals USA, Inc.$893
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$14,03099%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,130 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$54,200
Medicare patients
108
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$69,668
EliquisApixaban69$64,478
LinzessLinaclotide41$41,568
TrulicityDulaglutide17$35,943
XareltoRivaroxaban35$33,166
FarxigaDapagliflozin Propanediol20$27,323
OzempicSemaglutide28$25,672
MyrbetriqMirabegron52$25,540
MounjaroTirzepatide20$23,962
OxycontinOxycodone Hcl13$16,447
Repatha SureclickEvolocumab16$13,502
Breo ElliptaFluticasone/Vilanterol22$9,274
Incruse ElliptaUmeclidinium Bromide16$7,478
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate22$6,542
Atorvastatin Calcium309$4,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,016$69,66861 claims
PfizerEliquis$1,589$64,47869 claims
Lilly USA, LLCTrulicity, Mounjaro$1,960$59,90537 claims
AbbVieLinzess$2,070$41,56841 claims
Johnson & JohnsonXarelto$626$33,16635 claims
AstraZenecaFarxiga$1,294$27,32320 claims
Novo NordiskOzempic$499$25,67228 claims
Astellas Pharma US IncMyrbetriq$375$25,54052 claims
GSKBreo Ellipta, Incruse Ellipta$164$16,75238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →